Mitsubishi UFJ Trust & Banking Corp Acquires 7,758 Shares of Solventum Co. (NYSE:SOLV)

Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 245,800 shares of the company's stock after acquiring an additional 7,758 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.14% of Solventum worth $16,238,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SOLV. Vanguard Group Inc. increased its stake in Solventum by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock worth $1,074,591,000 after acquiring an additional 75,631 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Solventum in the fourth quarter worth approximately $3,406,000. Sei Investments Co. raised its stake in Solventum by 24.0% in the fourth quarter. Sei Investments Co. now owns 37,638 shares of the company's stock valued at $2,487,000 after purchasing an additional 7,295 shares in the last quarter. American Century Companies Inc. lifted its position in Solventum by 43.2% during the fourth quarter. American Century Companies Inc. now owns 146,608 shares of the company's stock valued at $9,685,000 after purchasing an additional 44,251 shares during the last quarter. Finally, Millstone Evans Group LLC purchased a new position in Solventum in the 4th quarter worth approximately $69,000.

Solventum Trading Up 0.9 %

NYSE:SOLV traded up $0.68 during midday trading on Wednesday, reaching $77.02. 390,935 shares of the stock traded hands, compared to its average volume of 1,420,772. The stock has a market capitalization of $13.32 billion and a P/E ratio of 28.00. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a fifty day moving average of $75.60 and a 200 day moving average of $71.97. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92.

Analysts Set New Price Targets

SOLV has been the topic of several research reports. Morgan Stanley raised their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. Piper Sandler upped their price objective on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a report on Friday, February 28th. Mizuho raised their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. Wells Fargo & Company upped their target price on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Finally, Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.